NYSE · ISRG
Healthcare · Medical - Instruments & Supplies
$432.01
Down-$16.75 (-3.73%)
Updated Oct 31, 2026, 3:47 PM
SID Score
5.4/10
Composite research score
Smart Money
39/100
Bearish
Price performance · ISRG
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ISRG closed at $432.01 after 21 trading sessions, up 10.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $453.60 | $453.60 | $431.1949 | $432.01 | 3.48M |
| Oct 29, 2026 | $447.85 | $450.40 | $443.475 | $448.76 | 1.89M |
| Oct 28, 2026 | $441.425 | $449.97 | $437.5101 | $444.18 | 1.85M |
| Oct 27, 2026 | $451.63 | $451.63 | $443.8501 | $445.88 | 1.7M |
| Oct 26, 2026 | $451.93 | $458.88 | $447.61 | $451.63 | 3.07M |
| Oct 23, 2026 | $443.65 | $458.45 | $442.56 | $452.29 | 3.01M |
| Oct 22, 2026 | $430.745 | $444.15 | $427.47 | $443.85 | 2.78M |
| Oct 21, 2026 | $402.495 | $432.7492 | $398.992 | $428.12 | 4.8M |
| Oct 20, 2026 | $433.502 | $440.40 | $432.00 | $438.00 | 3.44M |
| Oct 19, 2026 | $428.79 | $434.622 | $426.70 | $433.18 | 2.53M |
| Oct 16, 2026 | $428.43 | $434.89 | $425.51 | $426.70 | 2.61M |
| Oct 15, 2026 | $425.50 | $429.89 | $419.54 | $427.86 | 2.06M |
| Oct 14, 2026 | $424.81 | $425.50 | $414.65 | $420.24 | 1.92M |
| Oct 13, 2026 | $430.00 | $430.00 | $416.37 | $422.06 | 1.74M |
| Oct 12, 2026 | $423.00 | $429.27 | $421.03 | $427.64 | 1.62M |
| Oct 9, 2026 | $416.39 | $427.53 | $415.855 | $423.96 | 1.76M |
| Oct 8, 2026 | $411.60 | $416.72 | $407.70 | $415.41 | 2.53M |
| Oct 7, 2026 | $405.07 | $416.81 | $404.20 | $414.52 | 1.9M |
| Oct 6, 2026 | $405.20 | $409.34 | $402.00 | $404.76 | 1.65M |
| Oct 5, 2026 | $389.76 | $407.63 | $389.11 | $406.48 | 1.66M |
| Oct 2, 2026 | $405.15 | $406.47 | $391.39 | $391.95 | 1.83M |
The latest Smart Investors Daily articles mentioning ISRG.
Company
Market Activity
Research & News
ISRG research
Company profile and research snapshot.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Evercore ISI Group | In-Line | — |
| Oct 21, 2026 | Barclays | Overweight | — |
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 21, 2026 | Wells Fargo | Overweight | — |
| Oct 21, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Yahoo · Oct 30, 2026
DVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
Yahoo · Oct 29, 2026
Intuitive Surgical's third-quarter sales surged 22%, outpacing procedure growth. Can system placements, new technologies and recurring revenues offset pricing pressures?
Yahoo · Oct 29, 2026
BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.
Interpretive context generated from the platform’s current data sources.
Intuitive Surgical shares closed at $432.01, declining 0.85% in the most recent session, per SID market data. Over the trailing one-month period, the stock has gained 7.67%, while its three-month return stands at a stronger 15.08%. However, the one-year performance reflects a decline of 27.13%, underscoring significant longer-term pressure despite the recent recovery. Technically, ISRG trades above its 50-day moving average of $401.54, indicating near-term upward momentum, while hovering essentially at its 200-day moving average of $431.79. The 14-day RSI reads 52.4, placing the stock in neutral territory with no immediate overbought or oversold signal. According to Massive/Polygon data, average daily volume is approximately 2.26 million shares. The stock carries a beta of 1.686, reflecting substantially higher volatility than the broader market. Intuitive Surgical's market capitalization currently stands at approximately $195.5 billion.
Intuitive Surgical currently trades at a price-to-earnings ratio of 71.05, a significant premium relative to the broader Healthcare sector and the S&P 500 average, per SID market data. The company's PEG ratio stands at 13.30, suggesting that even when adjusting for expected earnings growth, the valuation remains elevated. According to SEC filings, the price-to-book ratio is 11.53, reflecting the market's substantial premium over the company's net asset value — consistent with investor expectations for continued dominance in robotic-assisted surgery. Intuitive Surgical pays no dividend, directing capital instead toward research, development, and platform expansion. The $195.5 billion market capitalization positions ISRG among the largest pure-play medical technology companies globally. These valuation metrics collectively indicate that the current share price embeds considerable growth expectations, requiring sustained revenue acceleration and margin expansion to justify the premium multiples relative to healthcare peers.
Intuitive Surgical's composite smart money score registers at 39 out of 100, generating a bearish signal according to SID market data. The institutional component scores a perfect 25 out of 25, reflecting robust fund-level ownership and conviction. However, the insider trading component scores just 5.0 out of 25, driven by a net-selling pattern. Per SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, comprising 7 purchases and 13 sales, indicating that company executives and directors have been net sellers of shares during the recent price recovery. The dark pool activity score stands at 8.5 out of 25, suggesting below-average institutional accumulation through off-exchange venues. Congressional trading activity is minimal, scoring only 0.8 out of 25. The divergence between strong institutional ownership and persistent insider selling creates a notable tension in the smart money landscape, with the aggregate score tilting bearish based on the weighted composite methodology.
Intuitive Surgical has delivered a consistent pattern of earnings beats across its three most recent reporting periods, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $3.00 against a consensus estimate of $2.54, representing a positive surprise of $0.46, or approximately 18.1%. The prior quarter saw EPS of $2.80 versus estimates of $2.41, a $0.39 beat. The quarter before that produced EPS of $2.50 against expectations of $1.92, delivering the largest surprise at $0.58, or roughly 30.2%. Analyst estimates for the upcoming quarter project EPS of $2.41. The sequential earnings trajectory — from $2.50 to $2.80 to $3.00 — demonstrates accelerating profitability over the three reported periods. Intuitive Surgical's next earnings report is scheduled for July 21, 2026, where investors will assess whether the company can sustain its pattern of exceeding consensus expectations.
Wall Street coverage of Intuitive Surgical remains predominantly constructive, with four of five tracked analysts maintaining bullish or positive ratings following the most recent earnings release, per SID consensus data. As of October 21, 2026, Barclays reiterated its Overweight rating, while Wells Fargo also maintained an Overweight stance. RBC Capital continued its Outperform designation, and TD Cowen reaffirmed a Buy rating. The sole neutral voice comes from Evercore ISI Group, which maintained its In-Line rating. Notably, none of the five analysts changed their ratings following the latest quarterly results, suggesting that the earnings beat of $0.46 per share was largely in line with buy-side expectations despite exceeding published consensus. According to Wall Street analyst reports, the uniformity of reiterated ratings — with zero downgrades or upgrades — indicates a stable consensus view. The 80% bullish composition among tracked analysts reflects continued confidence in Intuitive Surgical's competitive positioning in robotic surgery.
The latest Smart Investors Daily articles mentioning ISRG.
